Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

M. Zaretsky, Jesse; García-Díaz, Ángel; Sanghoon Shin, Daniel; Escuin-Ordinas, Helena; Hugo, Willy; Hu‐Lieskovan, Siwen; Y. Torrejon, Davis; Abril-Rodríguez, Gabriel; Sandoval, Salemiz; Barthly, Lucas; D. Saco, Justin; Homet Moreno, Blanca; Mezzadra, Riccardo; Chmielowski, Bartosz; Ruchalski, Kathleen; Peter Shintaku, I.; J. Sanchez, Phillip; Puig-Saus, Cristina; Cherry, Grace; Seja, Elizabeth; Kong, Xiangju; Pang, Jia; Berent-Maoz, Beata; Comı́n-Anduix, Begoña; G. Graeber, Thomas; C. Tumeh, Paul; N. Schumacher, Ton; S. Lo, Roger; Ribas, Antoni

doi:10.1056/nejmoa1604958

Public

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Published in New England Journal of Medicine • Jul 13, 2016

Authors:

Jesse M. Zaretsky

Ángel García-Díaz

Daniel Sanghoon Shin

Abstract

BACKGROUND: Approximately 75% of objective responses to anti-programmed death 1 (PD-1) therapy in patients with melanoma are durable, lasting for years, but delayed relapses have been noted long after initial objective tumor regression despite continuous therapy. Mechanisms of immune escape in this ...

Subject

Medicine

Melanoma

Context (archaeology)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!